• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
DougD

An Evening With David Tepper

Diary, Newsletter

?There is a time to make money, and a time to not lose money. This is one of those times.? That was the insightful gem I came away with after listening to my friend, hedge fund legend David Tepper.

Tepper continued, opining that the markets are ?dangerous? here, and that he was ?nervous.? ?It was easy to buy stocks (SPY), (QQQ), (IWM) in 2009 with an 11 price earnings multiple, but not so easy with a 17 multiple.?

He described the current investment environment as one of ?coordinated complacency,? where some central banks are providing just enough liquidity to prevent another crisis, but not enough to return us to more pronounced economic growth.

David said he would feel better if GDP growth returns to a 4% annual rate. If it stays stuck in the two?s, he just shrugged his shoulders.

If there is one person you drop everything for and listen to with rapt attention about the markets, it is the legendary hedge fund manager, David Tepper.

He is the best trader of our generation, bar none. If you gave him $1 million when he started Appaloosa Management LP in 1993, it would be worth a staggering $149 million today.

David argued that with China cutting costs and productivity improving thanks to technology, inflation will remain muted for some time to come.

That happened in the 19th century, when the productivity gains unleashed by the industrial revolution caused real prices to drop by half. I have been passionately arguing the same case myself for much of this year.

Tepper doesn?t see any glaring opportunities in the markets right now. At best, it is a mixed environment. He also remarked that that European Central Bank is far behind the curve. This does not augur well for the Euro (FXE).

Managing $20 billion in assets with a staff of only 33, David earned a personal paycheck of $3.5 billion in 2014, one of the largest in history. He was worth every penny.

His rise from a gritty inner city high school in Pittsburgh is now part of Wall Street lore. It is a classic American bootstrap story.

He moved on to Pitt College and Carnegie Melon for graduate school. He spent two years battling to keep a dying Republic Steel alive with innovative refinancings, even though he was hit with a 10% pay cut six weeks into the job.

That led to a gig as a junk bond analyst at Keystone Mutual Funds (now part of Evergreen Funds), and finally a coveted job at Goldman Sachs.

A mere six months after joining the firm, he was promoted to? head of convertible bond trading. He quickly became known as an iconoclast and innovator, gaining a loyal following of fans, first inside Goldman, and then throughout the industry at large.

I was one of those early acolytes, trading against him from the convertible bond desk at Morgan Stanley.

Tepper dispelled a myth that he named his firm ?Appaloosa? because he liked to eat horsemeat. In those primordial days, brokerage research was distributed by fax machines. Firms starting with the letter ?A? got the news up to 20 minutes earlier than competitors. Hey, anything to get an edge.

David suffered three 20% drawdowns during his career, once during the Russian debt default in 1998, and again in the 2008 crash. Each one was a sobering and humbling experience. Today he has returned profits to his clients that are double their original investment.

That means they are now playing with the ?house?s money.? This has lifted a great psychological burden from David?s shoulders, cleared his mind, and given him freedom. It is now impossible for his customers to lose money.

Tepper currently turns new money away and has closed some of his peripheral funds to concentrate his focus. He keeps working not to collect more assets, but for the love of the game.

David isn?t just sitting on his cash, he is giving great chunks of it away.

In 2003, he gave $55 million to his alma matter, now called the Carnegie Mellon David A. Tepper School of Business. Last year, he wrote another check to the school for $67 million. He has been active in Paul Tudor Jones? Robin Hood Foundation.

When super storm Hurricane Sandy devastated the east coast in 2012, he topped up many New Jersey charities that had been drained by the financial crisis.

Since then, Tepper has been able to deliver his best performance ever. Does he believe in karma? David pointed to himself with both hands with a big, bold flourish and said, ?This is karma!?

Asked if he had any advice for aspiring young hedge funds traders, he furrowed his brow and thought for a moment. ?The worse things are, the better they will get. When they are awful, it is a great time to buy.?

So true, so true.

I mentioned to David that a friend of mine?s father was a quarterback for the Pittsburgh Steelers during the 1950?s, in which he is now a part owner. He worked for $500 a month.

?It?s a little more expensive that that now,? he laughed, as an owner would. I?m going to that gentleman?s 80th birthday party in Chicago next weekend.

In parting, I thanked him for his great work, and said I could make a living just repeating to people what he said. He laughed again.

Good for you, David Tepper.

John Thomas - David Tepper

The Best Hedge Fund Managers in History

https://www.madhedgefundtrader.com/wp-content/uploads/2016/01/John-Thomas-David-Tepper.jpg 294 373 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-24 01:06:572023-02-13 14:11:44An Evening With David Tepper
Mad Hedge Fund Trader

Trade Alert - (SPY) #2 February 23, 2016

Trade Alert

As a potentially profitable opportunity presents itself, John will send you an alert with specific trade information as to what should be bought, when to buy it, and at what price. This is your chance to ?look over? John Thomas? shoulder as he gives you unparalleled insight on major world financial trends BEFORE they happen. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2011/10/slider-05-trader-alert.jpg 316 600 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2016-02-23 12:52:342016-02-23 12:52:34Trade Alert - (SPY) #2 February 23, 2016
Mad Hedge Fund Trader

Trade Alert - (SPY) February 23, 2016

Trade Alert

As a potentially profitable opportunity presents itself, John will send you an alert with specific trade information as to what should be bought, when to buy it, and at what price. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2016-02-23 11:53:512016-02-23 11:53:51Trade Alert - (SPY) February 23, 2016
DougD

February 23, 2016 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-23 09:08:192016-02-23 09:08:19February 23, 2016 - MDT Pro Tips A.M.
DougD

February 23, 2016

Diary, Newsletter, Summary

Global Market Comments
February 23, 2016
Fiat Lux

Featured Trade:
(WHERE DRIVERLESS CARS WILL TAKE US),
(TSLA), (AAPL), (GOOGL),
(AN AFTERNOON WITH GENERAL COLIN POWELL)

Tesla Motors, Inc. (TSLA)
Apple Inc. (AAPL)
Alphabet Inc. (GOOGL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-23 01:08:342016-02-23 01:08:34February 23, 2016
Mad Hedge Fund Trader

Trade Alert - (SPY) EXPIRATION February 22, 2016

Trade Alert

As a potentially profitable opportunity presents itself, John will send you an alert with specific trade information as to what should be bought, when to buy it, and at what price. This is your chance to ?look over? John Thomas? shoulder as he gives you unparalleled insight on major world financial trends BEFORE they happen. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2013/03/Alert.jpg 259 294 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2016-02-22 11:14:132016-02-22 11:14:13Trade Alert - (SPY) EXPIRATION February 22, 2016
Mad Hedge Fund Trader

Trade Alert - (SPY) EXPIRATION February 22, 2016

Trade Alert

As a potentially profitable opportunity presents itself, John will send you an alert with specific trade information as to what should be bought, when to buy it, and at what price. This is your chance to ?look over? John Thomas? shoulder as he gives you unparalleled insight on major world financial trends BEFORE they happen. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2013/03/Alert.jpg 259 294 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2016-02-22 11:08:352016-02-22 11:08:35Trade Alert - (SPY) EXPIRATION February 22, 2016
DougD

February 22, 2016 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-22 09:09:572016-02-22 09:09:57February 22, 2016 - MDT Pro Tips A.M.
DougD

February 22, 2016

Diary, Newsletter, Summary

Global Market Comments
February 22, 2016
Fiat Lux

Featured Trade:
(HOW LOW WILL BIOTECH GO?),
(IBB), (GILD), (CELG), (VRX),
(TESTIMONIAL)

Gilead Sciences Inc. (GILD)
iShares Nasdaq Biotechnology (IBB)
Celgene Corporation (CELG)
Valeant Pharmaceuticals International, Inc. (VRX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-21 01:08:592016-02-21 01:08:59February 22, 2016
DougD

How Low Will Biotech Go?

Diary, Newsletter

Long-term readers of this letter prospered mightily from my addiction to biotech stocks, one of the top performing sectors in the stock market during the first half of last year.

Readers made three round trips in hepatitis C drug developer Gilead Sciences (GILD) in the past four months, adding 5.77% to the value of their portfolios. I believe the company?s blockbuster drug will become the most profitable in history. So do a lot of others.

Longer-term investors bought the Biotech iShares ETF (IBB) on my advice, which gained an impressive 45% last year.

They certainly were getting downright frothy by June.

No less a figure than Federal Reserve governor Janet Yellen has indicated then that she thought valuations in the biotech sector were getting ?substantially stretched.? The Fed doesn?t single out stocks for commentary very often.

?Sell in May and go away,? turned out to be a brilliant strategy in 2015 because it got out of these stocks at all time highs with huge profits.

It was after that when the rot began.

It started when presidential candidate, Hillary Clinton, sent out the Tweet that sank biotech, warning that price controls and international drug competitions would be a high priority in her administration.

Then the bad boy antics of Martin Shkreli were exposed, who raised the price of an AIDS drug, Daraprim overnight by 55 fold. Nothing like focusing a spotlight on a big open sore. Shkreli is now under Federal indictment for operating a Ponzi scheme.

Then Valient (VRX), a target of activist Bill Ackamn, imploded.

The industry has barely had an up day since then.

My favorite, Gilead Sciences suffered a 33% nosedive, while the Biotech IShares ETF (IBB) sank by a gut churning 40%. Favorite Celgene (CELG) gave back 34%.

Is biotech gone for good? Is this once loved sector headed for the dustbin of history to join coal and 3-D printing?

I don?t think so. Far from the truth.

Big institutional investors and hedge funds that had the wisdom to raise cash at the end of 2015 are starting to circle in on this faded beauty, making lists, and taking names. And (GILD), the (IBB), and (CELG) are at the top of those lists. (VRX) isn?t.

Biotech has always been a hedge fund favorite.

That means hot money regularly flows in and out, giving the sector more than double the volatility of the main market. A 10% correction in any other stock is worth at least 25% in biotech. Now is one of the ?out? times.

This also makes biotech stocks great ones to buy on a dip. My last foray into (GILD) occurred after cautious guidance took the shares down a heart stopping 10% in a single day.

This is a great example of how unusually sensitive biotech stocks are to headline risk. I?ve ridden stocks to tremendous heights, watching them pour billions into a single treatment, only to see them crash and burn on failed stage three trials.

That is just the nature of their business. It?s all about ?all or nothing bets.?

Biotech is a high-risk sector that should only be held within a well diversified portfolio. You may notice that in the Mad Hedge Fund Trader?s model trading portfolio I never have more than 10% in biotech at any given time. I figure I could handle a total blow up and lose the whole 10% and still stay in business.

When I speak at conferences, strategy luncheons, and on TV, I tell listeners of my lazy man?s guide to long-term investment. Only follow three sectors, technology, biotech, and cyber security, and ignore the other 97. You?ll save yourself a lot of time reading pointless research.

Biotech currently accounts for a mere 1% of US GDP. It is on its way to 20%, about where big technology is today. That means that a disproportionately large share of earnings growth will spring from biotech over the coming decades.

One way to protect yourself is to stick with the big caps, which are undervalued relative to the sector as a while, and are expected to haul in 20% earnings growth this year.

Many smaller companies are at prices assuming a total certainty of the success of a single drug. The reality is that this only happens about half the time.

If you do go with small caps, I would take a venture capital approach. Buy a dozen with the expectation that many will go under, a coupled do OK, and one goes through the roof. Never put all your eggs in one basket. Or just buy the (IBB) which does this neat trick for you.

It also helps that you have someone with a scientific background making your picks, like myself.

Because drug companies promise such amazing results, like curing cancer, the sector has always been prone to hype and over promotion. I never met a biotech CEO who didn?t believe his company was about to deliver the next panacea, taking his shares up 100-fold, and delivering him a Nobel Prize.

One plus for biotech is that it has unusually strong patent protection, which usually extends out 20 years for new products. There are not a lot of Chinese companies that can imitate their drugs.

That means earnings can be predicted far into the future, and are largely immune from the economic cycle. If you?re sick, you want to get cured, regardless of whether the GDP is growing or shrinking, or whether interest rates are low or high.

And much of this cost is borne by the US government, through Obamacare and Medicare.

Make sure that your investments have plenty of new developments in the pipeline. Expiring patents on past winners with no replacements can spell certain death for a stock price.

I tell my kids that they will never suffer my medical maladies, as everything important will be cured within 20 years.

A century from now, historians will look back on our era and think ?Those poor people. They were so ignorant and helpless. They new nothing about medicine.? Our most modern treatments will appear to them like the application of leaches.

Publicly listed drug companies are now venturing into research fields that were only science fiction when I was in the lab 45 years go. ?Gene editing,? whereby genes can be repaired, edited, and then turned on and off at will, is now becoming a burgeoning new science.

It promises to cure the whole range of human maladies, including heart disease, cancer, obesity, and a whole range of degenerative diseases (including some of mine).

Expect to hear a lot more about TALENs (transcription activator-like effector nucleases) and CRISPR (clustered regular interspaced short palindromic repeats). You heard it here first.

What is truly fascinating is that hybrid computer science/biochemical scientists are now taking algorithms developed by the National Security Agency hackers and using them to decode human DNA. (I hope I?m not speaking too much out of school here).

Gene editing is the natural outcome of the discovery of recombinant DNA technology developed during the 1970?s by Paul Berg, Herbert Boyer, and Stanley Cohen, all early heroes of mine.

Since none were the equity participants of private companies, the initial rewards for the breakthrough were minimal. I remember that one received a new surfboard for his efforts.

Berg went on to found Genentech (GENE) in 1977 and got rich. If I hadn?t gone into the stock market, that is almost certainly where I would have ended up.

How things have changed.

The short answer here is that biotech does have further to run. A lot further.

The rate of innovation of biotechnology is accelerating so fast that it will continue to spew out fantastic investment opportunities for the rest of our lives.

So expect to receive many more Trade Alerts
in this area in the years to come.

But it is definitely an ?E? ticket ride. So fasten your seatbelt on your path to riches.

As for me, I am thrilled that I got to live so long to see his stuff happen. At times, it was a close run race.

GILD

IBB

CELG

VRX

SCIENTIST WITH TEST TUBEThis One Looks Like a Winner

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/SCIENTIST-WITH-TEST-TUBE-e1456014437770.png 269 400 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-02-21 01:07:002016-02-21 01:07:00How Low Will Biotech Go?
Page 116 of 133«‹114115116117118›»

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2026. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top